1. Home
  2. RANI vs UTSI Comparison

RANI vs UTSI Comparison

Compare RANI & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RANI
  • UTSI
  • Stock Information
  • Founded
  • RANI 2012
  • UTSI 1991
  • Country
  • RANI United States
  • UTSI China
  • Employees
  • RANI N/A
  • UTSI N/A
  • Industry
  • RANI Medicinal Chemicals and Botanical Products
  • UTSI Telecommunications Equipment
  • Sector
  • RANI Health Care
  • UTSI Telecommunications
  • Exchange
  • RANI Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • RANI 24.2M
  • UTSI 22.6M
  • IPO Year
  • RANI 2021
  • UTSI 2000
  • Fundamental
  • Price
  • RANI $2.12
  • UTSI $2.50
  • Analyst Decision
  • RANI Strong Buy
  • UTSI
  • Analyst Count
  • RANI 6
  • UTSI 0
  • Target Price
  • RANI $8.67
  • UTSI N/A
  • AVG Volume (30 Days)
  • RANI 44.1M
  • UTSI 4.8K
  • Earning Date
  • RANI 11-13-2025
  • UTSI 08-29-2025
  • Dividend Yield
  • RANI N/A
  • UTSI N/A
  • EPS Growth
  • RANI N/A
  • UTSI N/A
  • EPS
  • RANI N/A
  • UTSI N/A
  • Revenue
  • RANI $1,200,000.00
  • UTSI $9,793,000.00
  • Revenue This Year
  • RANI N/A
  • UTSI N/A
  • Revenue Next Year
  • RANI N/A
  • UTSI N/A
  • P/E Ratio
  • RANI N/A
  • UTSI N/A
  • Revenue Growth
  • RANI N/A
  • UTSI N/A
  • 52 Week Low
  • RANI $0.39
  • UTSI $1.84
  • 52 Week High
  • RANI $3.87
  • UTSI $3.22
  • Technical
  • Relative Strength Index (RSI)
  • RANI 65.39
  • UTSI 54.48
  • Support Level
  • RANI $1.76
  • UTSI $2.15
  • Resistance Level
  • RANI $3.87
  • UTSI $2.55
  • Average True Range (ATR)
  • RANI 0.45
  • UTSI 0.07
  • MACD
  • RANI 0.14
  • UTSI 0.01
  • Stochastic Oscillator
  • RANI 45.98
  • UTSI 88.61

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

Share on Social Networks: